MX2021000708A - Anticuerpos de cadena pesada que se unen al cd19. - Google Patents
Anticuerpos de cadena pesada que se unen al cd19.Info
- Publication number
- MX2021000708A MX2021000708A MX2021000708A MX2021000708A MX2021000708A MX 2021000708 A MX2021000708 A MX 2021000708A MX 2021000708 A MX2021000708 A MX 2021000708A MX 2021000708 A MX2021000708 A MX 2021000708A MX 2021000708 A MX2021000708 A MX 2021000708A
- Authority
- MX
- Mexico
- Prior art keywords
- heavy chain
- chain antibodies
- antibodies binding
- antibodies
- sup
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701281P | 2018-07-20 | 2018-07-20 | |
| PCT/US2019/042633 WO2020018922A1 (en) | 2018-07-20 | 2019-07-19 | Heavy chain antibodies binding to cd19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021000708A true MX2021000708A (es) | 2021-03-25 |
Family
ID=67515196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000708A MX2021000708A (es) | 2018-07-20 | 2019-07-19 | Anticuerpos de cadena pesada que se unen al cd19. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US12202898B2 (https=) |
| EP (2) | EP3823990B1 (https=) |
| JP (2) | JP7439046B2 (https=) |
| KR (2) | KR20260036383A (https=) |
| CN (2) | CN112351997B (https=) |
| AU (1) | AU2019305663B2 (https=) |
| BR (1) | BR112020024074A2 (https=) |
| CA (1) | CA3101069A1 (https=) |
| DK (1) | DK3823990T3 (https=) |
| FI (1) | FI3823990T3 (https=) |
| HR (1) | HRP20260372T1 (https=) |
| IL (2) | IL326259A (https=) |
| LT (1) | LT3823990T (https=) |
| MX (1) | MX2021000708A (https=) |
| PL (1) | PL3823990T3 (https=) |
| PT (1) | PT3823990T (https=) |
| SG (1) | SG11202011597RA (https=) |
| WO (1) | WO2020018922A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3029209A1 (en) | 2016-06-21 | 2017-12-28 | Teneobio, Inc. | Cd3 binding antibodies |
| IL264941B2 (en) | 2016-08-24 | 2025-12-01 | Teneobio Inc | Transgenic non-human animals producing modified heavy chain-only antibodies |
| FI4050034T3 (fi) | 2016-09-14 | 2024-06-10 | Teneoone Inc | Cd3:een sitoutuvia vasta-aineita |
| NZ754713A (en) | 2016-12-21 | 2025-11-28 | Teneobio Inc | Anti-bcma heavy chain-only antibodies |
| US11427642B2 (en) | 2017-06-20 | 2022-08-30 | Teneoone, Inc. | Anti-BCMA heavy chain-only antibodies |
| IL271194B2 (en) | 2017-06-20 | 2024-10-01 | Teneobio Inc | Anti-bcma heavy chain-only antibodies |
| WO2019126756A1 (en) | 2017-12-22 | 2019-06-27 | Teneobio, Inc. | Heavy chain antibodies binding to cd22 |
| PL3823990T3 (pl) | 2018-07-20 | 2026-04-20 | TeneoTwo, Inc. | Przeciwciała łańcucha ciężkiego wiążące się z cd19 |
| AU2020232691B2 (en) | 2019-03-05 | 2023-06-29 | Nkarta, Inc. | CD19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| JP7776987B2 (ja) | 2019-04-05 | 2025-11-27 | テネオバイオ， インコーポレイテッド | Ｐｓｍａに結合する重鎖抗体 |
| CN114206927B (zh) | 2019-06-14 | 2025-03-21 | 特尼奥生物股份有限公司 | 与cd22和cd3结合的多特异性重链抗体 |
| JP2023518049A (ja) | 2020-03-16 | 2023-04-27 | ユニバーシティ オブ サザン カリフォルニア | 新規な抗原結合ドメインおよびそれを組み込んだ合成抗原受容体 |
| TWI838621B (zh) | 2020-04-29 | 2024-04-11 | 美商泰尼歐萬公司 | 具有經修飾重鏈恆定區之多特異性重鏈抗體 |
| AU2021263448B2 (en) | 2020-04-29 | 2026-02-05 | Teneobio, Inc. | Multispecific heavy chain antibodies with modified heavy chain constant regions |
| KR20230038706A (ko) * | 2020-07-16 | 2023-03-21 | 난징 레전드 바이오테크 씨오., 엘티디. | Cd19 결합 분자 및 이의 용도 |
| JP7846667B2 (ja) | 2020-07-16 | 2026-04-15 | レジェンド バイオテック アイルランド リミテッド | Ｃｄ２０結合分子及びその使用 |
| EP4214233A1 (en) | 2020-09-16 | 2023-07-26 | Amgen Inc. | Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer |
| PE20232050A1 (es) * | 2021-04-06 | 2023-12-27 | Teneobio Inc | Anticuerpos anti-cd19 y estructuras car-t |
| WO2024243093A2 (en) * | 2023-05-19 | 2024-11-28 | The Regents Of The University Of California | Multispecific antibodies targeting cd3 and cd22 |
| EP4566619A1 (en) | 2023-12-08 | 2025-06-11 | AvenCell Therapeutics Inc. | Targeting modules against cd19 and cd20 for use in a method for stimulating a reversed chimeric antigen receptor-mediated immune response in a mammal |
| WO2025222102A1 (en) * | 2024-04-19 | 2025-10-23 | TeneoTwo, Inc. | Therapeutic combinations of acalabrutinib and a multispecific antibody to treat b-cell malignancies |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US6066721A (en) | 1995-07-06 | 2000-05-23 | Stanford University | Method to produce novel polyketides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| JP4046354B2 (ja) | 1996-03-18 | 2008-02-13 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 増大した半減期を有する免疫グロブリン様ドメイン |
| WO2001024812A1 (en) | 1999-10-06 | 2001-04-12 | N.V. Nutricia | USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA |
| UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
| US20030012783A1 (en) | 2001-02-20 | 2003-01-16 | Wayne Kindsvogel | Antibodies that bind both BCMA and TACI |
| GB0115256D0 (en) | 2001-06-21 | 2001-08-15 | Babraham Inst | Mouse light chain locus |
| WO2004042017A2 (en) | 2002-10-31 | 2004-05-21 | Genentech, Inc. | Methods and compositions for increasing antibody production |
| CA2513113A1 (en) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture |
| US20060008548A1 (en) | 2003-11-19 | 2006-01-12 | Invista North America S.A R.L. | Spinneret plate for producing a bulked continuous filament having a three-sided exterior cross-section and a convex six-sided central void |
| SI2311874T1 (sl) | 2004-07-22 | 2017-12-29 | Erasmus University Medical Center Rotterdam Department of Cell Biology and Genetics | Vezavne molekule |
| CN101218351A (zh) * | 2005-02-15 | 2008-07-09 | 杜克大学 | 抗cd19抗体及其在肿瘤学中的应用 |
| KR101335798B1 (ko) * | 2005-02-15 | 2013-12-02 | 듀크 유니버시티 | 항-ｃｄ19 항체 및 종양학에서 이의 용도 |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| DK2602323T3 (en) | 2007-06-01 | 2018-04-16 | Open Monoclonal Tech Inc | Compositions and Methods for Inhibiting Endogenous Immunoglobin Genes and Producing Transgenic Human Idiotypic Antibodies |
| US20100122358A1 (en) | 2008-06-06 | 2010-05-13 | Crescendo Biologics Limited | H-Chain-only antibodies |
| KR101314369B1 (ko) * | 2008-07-17 | 2013-10-10 | 노파르티스 아게 | 치료학적 항체에 대한 조성물 및 사용 방법 |
| EP2406284B9 (en) | 2009-03-10 | 2017-03-01 | Biogen MA Inc. | Anti-bcma antibodies |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| JP6636803B2 (ja) | 2013-02-05 | 2020-01-29 | エンクマフ エスアーエールエル | Ｂｃｍａに対する抗体の選択のための方法 |
| EA201790719A1 (ru) | 2014-09-26 | 2017-07-31 | Макродженикс, Инк. | Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения |
| CN105384825B (zh) * | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
| US9914683B2 (en) | 2016-05-26 | 2018-03-13 | X Development Llc | Fuel synthesis from an aqueous solution |
| CA3029209A1 (en) | 2016-06-21 | 2017-12-28 | Teneobio, Inc. | Cd3 binding antibodies |
| IL264941B2 (en) * | 2016-08-24 | 2025-12-01 | Teneobio Inc | Transgenic non-human animals producing modified heavy chain-only antibodies |
| FI4050034T3 (fi) | 2016-09-14 | 2024-06-10 | Teneoone Inc | Cd3:een sitoutuvia vasta-aineita |
| NZ754713A (en) | 2016-12-21 | 2025-11-28 | Teneobio Inc | Anti-bcma heavy chain-only antibodies |
| IL271194B2 (en) | 2017-06-20 | 2024-10-01 | Teneobio Inc | Anti-bcma heavy chain-only antibodies |
| US11427642B2 (en) | 2017-06-20 | 2022-08-30 | Teneoone, Inc. | Anti-BCMA heavy chain-only antibodies |
| US20200138865A1 (en) | 2017-06-30 | 2020-05-07 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Anti-b-cell maturation antigen chimeric antigen receptors with human domains |
| RU2020124623A (ru) | 2017-12-27 | 2022-01-27 | Тенеобио, Инк. | Антитела, специфичные к гетеродимеру cd3-дельта/эпсилон |
| SG11202011589WA (en) | 2018-05-24 | 2020-12-30 | Ayala Pharmaceuticals Inc | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and immunotherapeutics and methods of use thereof |
| PL3823990T3 (pl) | 2018-07-20 | 2026-04-20 | TeneoTwo, Inc. | Przeciwciała łańcucha ciężkiego wiążące się z cd19 |
| CN114206927B (zh) | 2019-06-14 | 2025-03-21 | 特尼奥生物股份有限公司 | 与cd22和cd3结合的多特异性重链抗体 |
| AU2021263448B2 (en) | 2020-04-29 | 2026-02-05 | Teneobio, Inc. | Multispecific heavy chain antibodies with modified heavy chain constant regions |
-
2019
- 2019-07-19 PL PL19749123.6T patent/PL3823990T3/pl unknown
- 2019-07-19 CA CA3101069A patent/CA3101069A1/en active Pending
- 2019-07-19 EP EP19749123.6A patent/EP3823990B1/en active Active
- 2019-07-19 JP JP2021502833A patent/JP7439046B2/ja active Active
- 2019-07-19 IL IL326259A patent/IL326259A/en unknown
- 2019-07-19 MX MX2021000708A patent/MX2021000708A/es unknown
- 2019-07-19 CN CN201980035712.8A patent/CN112351997B/zh active Active
- 2019-07-19 US US17/260,213 patent/US12202898B2/en active Active
- 2019-07-19 AU AU2019305663A patent/AU2019305663B2/en active Active
- 2019-07-19 BR BR112020024074-5A patent/BR112020024074A2/pt unknown
- 2019-07-19 CN CN202310539593.8A patent/CN116769032A/zh active Pending
- 2019-07-19 SG SG11202011597RA patent/SG11202011597RA/en unknown
- 2019-07-19 WO PCT/US2019/042633 patent/WO2020018922A1/en not_active Ceased
- 2019-07-19 DK DK19749123.6T patent/DK3823990T3/da active
- 2019-07-19 PT PT197491236T patent/PT3823990T/pt unknown
- 2019-07-19 EP EP25219867.6A patent/EP4714502A2/en active Pending
- 2019-07-19 LT LTEPPCT/US2019/042633T patent/LT3823990T/lt unknown
- 2019-07-19 KR KR1020267005215A patent/KR20260036383A/ko active Pending
- 2019-07-19 HR HRP20260372TT patent/HRP20260372T1/hr unknown
- 2019-07-19 FI FIEP19749123.6T patent/FI3823990T3/fi active
- 2019-07-19 KR KR1020207034987A patent/KR102930803B1/ko active Active
-
2020
- 2020-11-26 IL IL279010A patent/IL279010B1/en unknown
-
2024
- 2024-02-14 JP JP2024020312A patent/JP7737488B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7439046B2 (ja) | 2024-02-27 |
| WO2020018922A1 (en) | 2020-01-23 |
| CN112351997A (zh) | 2021-02-09 |
| LT3823990T (lt) | 2026-04-10 |
| CN116769032A (zh) | 2023-09-19 |
| US12202898B2 (en) | 2025-01-21 |
| US20210332133A1 (en) | 2021-10-28 |
| EP4714502A2 (en) | 2026-03-25 |
| JP2024073430A (ja) | 2024-05-29 |
| EP3823990A1 (en) | 2021-05-26 |
| CA3101069A1 (en) | 2020-01-23 |
| KR20260036383A (ko) | 2026-03-16 |
| PL3823990T3 (pl) | 2026-04-20 |
| HRP20260372T1 (hr) | 2026-04-24 |
| AU2019305663B2 (en) | 2026-04-02 |
| SG11202011597RA (en) | 2020-12-30 |
| CN112351997B (zh) | 2023-05-26 |
| EP3823990B1 (en) | 2025-12-17 |
| BR112020024074A2 (pt) | 2021-02-17 |
| AU2019305663A1 (en) | 2021-03-11 |
| FI3823990T3 (fi) | 2026-03-16 |
| IL279010A (en) | 2021-01-31 |
| KR20210032311A (ko) | 2021-03-24 |
| IL326259A (en) | 2026-03-01 |
| JP2021530236A (ja) | 2021-11-11 |
| DK3823990T3 (da) | 2026-03-16 |
| KR102930803B1 (ko) | 2026-02-26 |
| PT3823990T (pt) | 2026-03-20 |
| IL279010B1 (en) | 2026-03-01 |
| JP7737488B2 (ja) | 2025-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021000708A (es) | Anticuerpos de cadena pesada que se unen al cd19. | |
| CR20210500A (es) | Anticuerpos de cadena pesada que se unen al psma | |
| CR20200322A (es) | Anticuerpos de cadena pesada que se unen a cd22 | |
| ZA202311311B (en) | Anti-bcma heavy chain-only antibodies | |
| CR20210622A (es) | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 | |
| PH12021550337A1 (en) | Anti-gdf15 antibodies, compositions and methods of use | |
| MX2024014319A (es) | Anticuerpos anti-bcma unicamente de cadena pesada | |
| ZA201903985B (en) | Anti-bcma heavy chain-only antibodies | |
| ZA202201874B (en) | Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies | |
| PH12018502225A1 (en) | Anti-il-33 antibodies, compositions, methods and uses thereof | |
| MX2020012797A (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso. | |
| PH12018500707A1 (en) | Anti-human cd19 antibodies with high affinity | |
| MX392069B (es) | Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos. | |
| SA517381703B1 (ar) | C10orf54 - أجسام مضادة لـ واستخداماتها | |
| MX2022016342A (es) | Union de anticuerpos multiespecificos a bcma. | |
| PH12016501366A1 (en) | Novel anti-baff antibodies | |
| EA201890158A1 (ru) | Антитела против ntb-a и связанные композиции и способы | |
| PH12020550908A1 (en) | Anti-cxcr5 antibodies and compositions and uses thereof | |
| MX2023011725A (es) | Anticuerpos anti-cd19 y estructuras car-t. | |
| MX2021004732A (es) | Anticuerpos de cadena pesada que se unen a cd38. | |
| MY205689A (en) | Antibody molecules to cd138 and uses thereof | |
| MX2017003014A (es) | Anticuerpos anti-alfa v beta 5 humanizados y usos de estos. | |
| EA202090128A3 (ru) | Антитела против антигена 2 дендритных клеток крови и их применение |